PhRMA: use FDA logo for link to PI, patient info online

Share this article:
PhRMA called for FDA to develop an agency icon or bug that drugmakers could use on their websites to link to agency-approved product information and patient medical guides.

“Going forward, the agency could promote the responsible use of the internet to benefit patients by shining a brighter spotlight on legitimate, FDA-regulated health communication,” said PhRMA SVP Ken Johnson in a statement. “Leveraging the FDA's logo—or a universal FDA-approved graphic symbol—in search results and throughout the web would inform patients, at a glance, that they ware visiting a legitimate site that contains comprehensive FDA-regulated benefit and risk information.”

Such a logo, PhRMA suggested, could include a “universal warning statement” noting that all drugs carry risks and inviting viewers to “click here for more information,” the group said, “to provide an indication of risk when there is little space.”

The  agency also hailed the FTC's approach to space-limited formats like Twitter and paid search, and urged FDA to “facilitate communication of abbreviated benefit and risk information,” given a prominent link to full indication and risk information. The group suggested that “such information could be provided using roll-over or pop-up technology.”

The proposals come as a preamble to the trade group's testimony at FDA's public hearings on internet and social media promotion of regulated products later this week.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...